IDO1 and myeloid sarcoma: Initially, induction of the KP (i.e., up-regulation of IDO-1) may be beneficial as IDO-1 mediates an immunomodulatory effect in MS that partially explains the therapeutic effect exerted by interferons4 and vitamin D30 in early-mild stages of MS.